SAN FRANCISCO--(BUSINESS WIRE)--Prosetta Biosciences, Inc. (the “Company,” or “Prosetta”), today announced that it has entered into a Feasibility and First Right of Negotiation Agreement (the "Agreement") with Takeda Pharmaceutical Company Limited ("Takeda"), to conduct a feasibility study for the future development of novel compounds for diseases and disorders impacting the central nervous system ("CNS"). Prosetta is a biotechnology company that is dedicated to the discovery, development and c
![]()
↧